Patents by Inventor Raphael Darteil

Raphael Darteil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 11103484
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: August 31, 2021
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10905680
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: February 2, 2021
    Assignee: GENFIT
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS
    Publication number: 20200384105
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Application
    Filed: June 17, 2020
    Publication date: December 10, 2020
    Inventors: Raphael DARTEIL, Rémy Hanf, Dean Hum, Ingrid Dufour
  • METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
    Publication number: 20200316031
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 8, 2020
    Inventors: Raphael DARTEIL, Robert WALCZAK, Carole BELANGER, Emilie NEGRO, Pierre DAUBERSIES, Philippe DELATAILLE
  • Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
    Patent number: 10722575
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: July 28, 2020
    Assignee: GENFIT
    Inventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
  • NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS
    Publication number: 20190352715
    Abstract: The invention relates to a novel method for the diagnosis of non-alcoholic steatohepatitis (NASH), and for classifying a subject as a potential receiver of a treatment for NASH.
    Type: Application
    Filed: March 30, 2017
    Publication date: November 21, 2019
    Applicant: Genfit
    Inventors: Raphael Darteil, Geneviève Cordonnier, John Brozek, Emilie Praca, Fouad Ben Sudrik
  • USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS
    Publication number: 20190275146
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Application
    Filed: May 29, 2019
    Publication date: September 12, 2019
    Inventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
  • Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
    Patent number: 10350181
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: July 16, 2019
    Assignee: GENFIT
    Inventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
  • METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
    Publication number: 20190083468
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Application
    Filed: December 4, 2018
    Publication date: March 21, 2019
    Inventors: Raphael DARTEIL, Robert WALCZAK, Carole BELANGER, Emilie NEGRO, Pierre DAUBERSIES, Philippe DELATAILLE
  • METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
    Publication number: 20190000813
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Application
    Filed: September 19, 2018
    Publication date: January 3, 2019
    Inventors: Raphael DARTEIL, Robert WALCZAK, Carole BELANGER, Emilie NEGRO, Pierre DAUBERSIES, Philippe DELATAILLE
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10130612
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: November 20, 2018
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10130613
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: November 20, 2018
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10117856
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: November 6, 2018
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10117855
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: November 6, 2018
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS
    Publication number: 20180280328
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 4, 2018
    Inventors: Raphael DARTEIL, Rémy HANF, Dean HUM, Ingrid DUFOUR
  • Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
    Patent number: 10022343
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: July 17, 2018
    Assignee: GENFIT
    Inventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
  • METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
    Publication number: 20180092886
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 5, 2018
    Inventors: Raphael DARTEIL, Robert WALCZAK, Carole BELANGER, Emilie NEGRO, Pierre DAUBERSIES, Philippe DELATAILLE
  • METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
    Publication number: 20180092884
    Abstract: The present invention relates to the compound [2-[(5-nitro-1, 3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 5, 2018
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
    Publication number: 20180092885
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 5, 2018
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
    Publication number: 20180085354
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Application
    Filed: December 11, 2017
    Publication date: March 29, 2018
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille